Junichi Watanabe
ASKA Pharmaceutical Co. Ltd.
Research and Development Division
Takatsu-ku
Kawasaki-shi
Japan
Name/email consistency: high
- The inhibitory effect of docetaxel and p38 MAPK inhibitor on TZT-1027 (Soblidotin)-induced antivascular activity. Watanabe, J., Natsume, T., Kobayashi, M. Anticancer Res. (2007)
- Comparison of the antivascular and cytotoxic activities of TZT-1027 (Soblidotin) with those of other anticancer agents. Watanabe, J., Natsume, T., Kobayashi, M. Anticancer. Drugs (2007)
- Antivascular effects of TZT-1027 (Soblidotin) on murine Colon26 adenocarcinoma. Watanabe, J., Natsume, T., Kobayashi, M. Cancer Sci. (2006)
- Antitumor activity of TZT-1027 (Soblidotin). Watanabe, J., Minami, M., Kobayashi, M. Anticancer Res. (2006)